Conference Coverage
The Case Against Antibody Drug Conjugates for Patients With Lung Cancers
Corey Langer, MD
05/15/2024
At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Corey Langer, MD, Abramson Cancer Center, Philadelphia, Pennsylvania, argued that antibody drug conjugates are not ready to replace TROP-2 inhibitors as the standard of care for patients with lung cancers.
Source:
Langer C. Debate: ADCs: The new emperor or the emperor’s new clothes. Presented at Great Debates & Updates in Lung Cancer; April 27-28, 2024; New York, NY.